Marks Group Wealth Management Inc Sells 231 Shares of Stryker Co. (NYSE:SYK)

Marks Group Wealth Management Inc lessened its holdings in Stryker Co. (NYSE:SYK) by 0.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 52,705 shares of the medical technology company’s stock after selling 231 shares during the quarter. Stryker makes up approximately 1.9% of Marks Group Wealth Management Inc’s holdings, making the stock its 3rd biggest holding. Marks Group Wealth Management Inc’s holdings in Stryker were worth $18,976,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Dunhill Financial LLC boosted its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Stryker in the 3rd quarter valued at about $36,000. Activest Wealth Management acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $36,000. Crews Bank & Trust bought a new position in Stryker during the 4th quarter worth approximately $39,000. Finally, Hara Capital LLC acquired a new position in Stryker during the third quarter valued at approximately $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.5 %

Shares of SYK stock opened at $390.52 on Wednesday. The firm’s fifty day moving average price is $377.28 and its two-hundred day moving average price is $365.59. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $148.88 billion, a P/E ratio of 50.33, a PEG ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 EPS. On average, equities analysts predict that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. Citigroup increased their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Barclays boosted their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $420.68.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.